JP2012520446A5 - - Google Patents

Download PDF

Info

Publication number
JP2012520446A5
JP2012520446A5 JP2011553450A JP2011553450A JP2012520446A5 JP 2012520446 A5 JP2012520446 A5 JP 2012520446A5 JP 2011553450 A JP2011553450 A JP 2011553450A JP 2011553450 A JP2011553450 A JP 2011553450A JP 2012520446 A5 JP2012520446 A5 JP 2012520446A5
Authority
JP
Japan
Prior art keywords
monitoring
biomarker
cells
methyl
dim
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2011553450A
Other languages
English (en)
Japanese (ja)
Other versions
JP5667581B2 (ja
JP2012520446A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/EP2010/053063 external-priority patent/WO2010103058A1/en
Publication of JP2012520446A publication Critical patent/JP2012520446A/ja
Publication of JP2012520446A5 publication Critical patent/JP2012520446A5/ja
Application granted granted Critical
Publication of JP5667581B2 publication Critical patent/JP5667581B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2011553450A 2009-03-12 2010-03-11 治療をモニターするためのバイオマーカーを使用した方法またはシステム Expired - Fee Related JP5667581B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP09154964 2009-03-12
EP09154964.2 2009-03-12
PCT/EP2010/053063 WO2010103058A1 (en) 2009-03-12 2010-03-11 Method or system using biomarkers for the monitoring of a treatment

Publications (3)

Publication Number Publication Date
JP2012520446A JP2012520446A (ja) 2012-09-06
JP2012520446A5 true JP2012520446A5 (enExample) 2013-04-25
JP5667581B2 JP5667581B2 (ja) 2015-02-12

Family

ID=42129920

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2011553450A Expired - Fee Related JP5667581B2 (ja) 2009-03-12 2010-03-11 治療をモニターするためのバイオマーカーを使用した方法またはシステム

Country Status (24)

Country Link
US (1) US8802384B2 (enExample)
EP (1) EP2406628A1 (enExample)
JP (1) JP5667581B2 (enExample)
KR (1) KR20110137307A (enExample)
CN (1) CN102334030A (enExample)
AR (1) AR076113A1 (enExample)
AU (1) AU2010223256B2 (enExample)
BR (1) BRPI1011688A2 (enExample)
CA (1) CA2755055A1 (enExample)
CL (1) CL2011002260A1 (enExample)
CO (1) CO6430497A2 (enExample)
EA (1) EA201101300A1 (enExample)
EC (1) ECSP11011323A (enExample)
IL (1) IL214747A0 (enExample)
MA (1) MA33120B1 (enExample)
MX (1) MX2011009482A (enExample)
NZ (1) NZ594843A (enExample)
PE (1) PE20120592A1 (enExample)
SG (1) SG174324A1 (enExample)
TN (1) TN2011000457A1 (enExample)
TW (1) TW201100802A (enExample)
UA (1) UA107789C2 (enExample)
UY (1) UY32482A (enExample)
WO (1) WO2010103058A1 (enExample)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20170065529A1 (en) 2015-09-09 2017-03-09 Boehringer Ingelheim International Gmbh Pharmaceutical dosage form for immediate release of an indolinone derivative
UA107560C2 (uk) * 2008-06-06 2015-01-26 Фармацевтична лікарська форма для негайного вивільнення похідної індолінону
NO2299987T3 (enExample) * 2008-06-06 2018-07-21
US20140350022A1 (en) 2013-05-10 2014-11-27 Boehringer Ingelheim International Gmbh Efficacious treatment of NSCLC and predictive clinical marker of the responsiveness of a tumour to a treatment
CN104003925B (zh) * 2013-06-05 2016-03-30 四川大学 吲哚酮化合物或其衍生物及其用途
US20150044288A1 (en) 2013-07-31 2015-02-12 Windward Pharma, Inc. Aerosol tyrosine kinase inhibitor compounds and uses thereof
WO2018081236A1 (en) * 2016-10-28 2018-05-03 Cedars-Sinai Medical Center Method of predicting progression of idiopathic pulmonary fibrosis and monitoring of therapeutic efficacy

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6762180B1 (en) * 1999-10-13 2004-07-13 Boehringer Ingelheim Pharma Kg Substituted indolines which inhibit receptor tyrosine kinases
UA75054C2 (uk) 1999-10-13 2006-03-15 Бьорінгер Інгельхайм Фарма Гмбх & Ко. Кг Заміщені в положенні 6 індолінони, їх одержання та їх застосування як лікарського засобу
DE10233500A1 (de) 2002-07-24 2004-02-19 Boehringer Ingelheim Pharma Gmbh & Co. Kg 3-Z-[1-(4-(N-((4-Methyl-piperazin-1-yl)-methylcarbonyl)-N-methyl-amino)-anilino)-1-phenyl-methylen]-6-methoxycarbonyl-2-indolinon-Monoethansulfonat und dessen Verwendung als Arzneimittel
US20040204458A1 (en) 2002-08-16 2004-10-14 Boehringer Ingelheim Pharma Gmbh & Co. Kg Use of Lck inhibitors for treatment of immunologic diseases
DE10237423A1 (de) 2002-08-16 2004-02-19 Boehringer Ingelheim Pharma Gmbh & Co. Kg Verwendung von LCK-Inhibitoren für die Behandlung von immunologischen Erkrankungen
US20050043233A1 (en) 2003-04-29 2005-02-24 Boehringer Ingelheim International Gmbh Combinations for the treatment of diseases involving cell proliferation, migration or apoptosis of myeloma cells or angiogenesis
EP1571225A1 (en) 2004-03-02 2005-09-07 PrimaGen Holding B.V. Diagnosis of a disease and monitoring of therapy using the AC133 gene
PE20060777A1 (es) 2004-12-24 2006-10-06 Boehringer Ingelheim Int Derivados de indolinona para el tratamiento o la prevencion de enfermedades fibroticas
EP1777523A1 (en) 2005-10-19 2007-04-25 INSERM (Institut National de la Santé et de la Recherche Médicale) An in vitro method for the prognosis of progression of a cancer and of the outcome in a patient and means for performing said method
EP2008103B1 (en) 2006-04-18 2010-07-28 Wellstat Biologics Corporation Detection of circulating endothelial cells
EP1870400A1 (en) 2006-06-08 2007-12-26 Boehringer Ingelheim Pharma GmbH & Co. KG Salts and crystalline salt forms of an 2-indolinone derivative
CN101512017A (zh) * 2006-09-07 2009-08-19 阿斯利康(瑞典)有限公司 评价用靶向ret受体酪氨酸激酶的药物治疗的患者的方法
EP2527467A3 (en) 2007-04-13 2013-03-20 Bristol-Myers Squibb Company Biomarkers and methods for determining sensitivity to vascular endothelial growth factor receptor-2 modulators
US20100184049A1 (en) 2007-04-27 2010-07-22 Steve Goodison Glycoprotein Profiling of Bladder Cancer

Similar Documents

Publication Publication Date Title
JP2012520446A5 (enExample)
Wang et al. Sertraline and its metabolite desmethylsertraline, but not bupropion or its three major metabolites, have high affinity for P-glycoprotein
Zhang et al. Linc‐MAF‐4 regulates Th1/Th2 differentiation and is associated with the pathogenesis of multiple sclerosis by targeting MAF
JP2016500110A5 (enExample)
RU2017126701A (ru) Способ детекции нуклеосом, содержащих нуклеотиды
JP2014512006A5 (enExample)
JP2016513094A5 (enExample)
JP2016118568A5 (enExample)
JP2009536828A5 (enExample)
JP6755241B2 (ja) 新規分子バイオマーカーを使用して慢性閉塞性肺疾患(copd)を診断する方法
JP2013178260A5 (enExample)
JP2011177182A5 (enExample)
JP6755242B2 (ja) 新規分子バイオマーカーを使用して慢性閉塞性肺疾患(copd)を診断する方法
RU2010101909A (ru) Способ выявления или лечения реакции "трансплантат против хозяина"
JunHui et al. Reduced number and activity of circulating endothelial progenitor cells from patients with hyperhomocysteinemia
JP5667581B2 (ja) 治療をモニターするためのバイオマーカーを使用した方法またはシステム
RU2009106718A (ru) Применение белка с меланома-ингибирующей активностью (миа) в качестве раннего индикатора терапевтического ответа при меланоме
Baggett et al. Myofibroblast senescence promotes arrhythmogenic remodeling in the aged infarcted rabbit heart
JP2013543581A5 (enExample)
JP2013522589A5 (enExample)
ES2616808T3 (es) Métodos de base biomecánica de diagnóstico de escoliosis
Gong et al. Tumor microenvironment properties are associated with low CD68-positive cell infiltration and favorable disease-free survival in EGFR-mutant lung adenocarcinoma
Duckworth et al. An investigation of the effect of the prostaglandin EP2 receptor agonist, butaprost, on the human isolated myometrium from pregnant and non-pregnant women
JP2013526863A5 (enExample)
JP2012524537A5 (enExample)